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ABSTRACT OF THE DISSERTATION
Sleep-wake Cycle Assessment in Type 2 Diabetes and Salivary Melatonin Correlates

by
Paula Regina Aguiar Cavalcanti
Doctor of Science, Graduate Program in Physical Therapy
Loma Linda University, June 2013
Dr. Lee Berk, Chairperson

The aim of this study was to analyze the sleep-wake cycle of T2DM subjects and
compare it to healthy controls using the nonparametric approach and to assess the
changes in the circadian and homeostatic control of the sleep-wake cycle in type 2
diabetic (T2DM) and correlate it with melatonin concentration. The sample consisted of
21 subjects with diagnosis of T2DM for more than a year and 21 healthy controls
matched for gender and age. Subjects were assessed using the Beck’s Depression
Inventory (BDI), the Apnea Risk Evaluation System (ARES), hemoglobin A1c (HbA1c),
actigraphy and melatonin levels. The findings revealed that T2DM subjects demonstrate
lower IS (p=.03), higher IV (p=.046) and lower rhythm amplitude (p=.02) when
compared to healthy controls. Mean melatonin concentrations collected at bed time were
significantly lower in the diabetic subjects than that of controls (11.7±7.27 pg/ml vs.
24.13±10.80pg/ml; p<.01). Actigraphic analysis during the wake phase demonstrated that
diabetic subjects showed lower levels of activity (p=.02). Additionally, there was a
significant difference decrease in sleep duration (p=.03), efficiency (p=.02); and higher
activity counts during the sleep phase (p=.02) in the diabetic group. Sleep efficiency was
significantly correlated with melatonin collected two hours before bed time (ρ=.61;
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p=.047). Additionally, there were significant inverse relationships between melatonin
collected at two hours before bed time and latency (ρ=-.87; p=.001), wake after sleep
onset (ρ =-.69; p=.02) and nocturnal activity (ρ =-.67; p=.03). Latency was inversely
correlated with melatonin collected at bed time (ρ =-.69; p=.02). These findings suggest
that T2DM presents disturbances in the homeostatic and circadian drives, mainly
characterized by less consistency across days of the daily circadian signal, higher rhythm
fragmentation and lower rhythm amplitude. In addition to the lower melatonin levels, the
decrease in the amplitude of the activity rhythm may also be involved in circadian
alterations of the sleep-wake cycle.
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CHAPTER ONE
INTRODUCTION

Diabetes and Sleep Dysfunction
There are approximately 25.8 million individuals with diabetes in the United
States; of whom 90% to 95% are classified as type 2 diabetes mellitus (T2DM)
(Department of Health and Human Services, 2011). Moreover, prediabetes has been
predicted in around 79 million Americans (Department of Health and Human Services,
2011). T2DM is characterized by insulin resistance accompanied by impaired insulin
secretion (Kahn, 2003). Insulin resistance and T2DM are both associated with an
increased risk of cardiovascular disease (Kashyap & Defronzo, 2007).
According to Wild et al., 2004, the number of people diagnosed with T2DM will
increase to 366 million by 2030, and countries such as China, India, the Middle East and
sub-Saharan Africa will probably have the highest increase (Wild et al., 2004). Patients
with diabetes have an augmented chance to develop coronary artery and peripheral
vascular disease, stroke, blindness and renal failure; which lead to a significant increase
in costs to the public health system (Yach et al., 2006). Among the most common studies,
risk factors for T2DM include: unhealthy diet, smoking, physical inactivity, obesity, and
alcohol abuse (American Diabetes Association, 2003). The Centers for Disease Control
and Prevention have reported that sleep complaints have a high incidence rate in the
United State’s diabetic population, and individuals with diabetes are more likely to have
sleep impairments when compared to healthy controls (Plantinga et al., 2012).
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Sleep disturbances, such as obstructive sleep apnea (OSA) (Ip et al., 2002),
inadequate sleep duration (Spiegel et al., 2005; Van Cauter et al., 2007b), insomnia,
restless leg syndrome and poor sleep quality are associated with an increased risk of
developing chronic systemic conditions (Gangwisch et al., 2005; Gangwisch et al., 2006).
Metabolic syndrome (Jennings et al., 2007; Hall et al., 2008), including hypertension
(Gangwisch et al., 2006), obesity (Hasler et al., 2004; Gangwisch et al., 2005), and
cardiovascular disease (Nilsson et al., 2001), have been described as such conditions that
are directly related to sleep disturbances. Furthermore, sleep disorders have been both
identified as a risk factor for developing T2DM (Knutson et al., 2006; Tasali et al., 2009),
as well as associated with aggravation of the diabetes condition (Nilsson et al., 2004;
Hayashino et al., 2007).
The main connections between type 2 diabetes and poor sleep have been
attributed to impairments in glucose metabolism and circadian variation of hormone
levels (Gottlieb et al., 2005; Van Cauter et al., 2007a; Spiegel et al., 2009). Glucose
tolerance and insulin secretion are adjusted according to the sleep-wake cycle (Van
Cauter et al., 1991). The homeostasis of normal glucose metabolic process is directly
influenced by inadequate sleep through disruption of circadian rhythms, clock gene
function and variation in autonomic nervous system activity (Laposky et al., 2008;
Gangwisch, 2009). Moreover, glucose consumption is greatest during wake and lowest
during non-rapid eye movement (NREM) sleep; also glucose metabolism expresses a
diurnal pattern with variations in glucose tolerance throughout the day (Van Cauter et al.,
1991; Scheen et al., 1996).
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Sleep deprivation is one of the most studied sleep disturbances in T2DM.
Associations between reduced sleep duration and high glucose levels have been
previously reported. This relationship has been mainly explained by the reduced glucose
metabolism, increased insulin resistance and high cortisol concentrations (Vgontzas et al.,
1999; Gottlieb et al., 2005; Nedeltcheva et al., 2009a; Spiegel et al., 2009; Buxton et al.,
2010). Experimental studies in healthy individuals have reported that restricting sleep to
four hours for a period of two or more nights, reduce glucose tolerance by 40%, and acute
insulin response to glucose by 30% (Spiegel et al., 1999; Spiegel et al., 2005). Another
study showed that even one night of sleep restriction has negative effects on glucose
metabolism in healthy individuals (Donga et al., 2010).
Results from the Sleep Heart Health Study showed that sleeping six hours or less,
and sleeping nine hours or more per night have a greater prevalence of type 2 diabetes
and impaired glucose tolerance when compared to people sleeping seven to eight hours
per night (Gottlieb et al., 2005). Data from cross-sectional studies suggest that short and
long duration of sleep are associated with increased prevalence of metabolic dysfunction
with greater occurrence of high fasting plasma glucose and high Hemoglobin A1c
(HbA1c) level (Gottlieb et al., 2005; Nakajima et al., 2008). Furthermore, quality and
amount of sleep were reported to be a significant predictor of HbA1c (Knutson et al.,
2006). Indeed, sleep duration above eight hours per day or less than seven hours per day
are at a moderately increased risk of all-cause of mortality, cardiovascular disease, and
symptomatic diabetes (Phillips et al., 2006).
Leptin, a hormone secreted during sleep, has also been associated with metabolic
consequences of sleep disturbances (Spiegel et al., 2009). Its action is linked with the
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balance between satiety and the need for food and energy consumption. The levels of
Ghrelin tend to decrease throughout the night and the level of leptin tend to elevate (Van
Cauter et al., 1991; Simon et al., 1994). Hypersecretion of leptin is observed during sleep
deprivation, which leads to increase food intake, and blood glucose levels (Nedeltcheva
et al., 2009b). Sleep apnea has also been reported to be related to the increase of leptin
concentration and the increase in resistance to leptin action (Patel et al., 2004). This
condition is one of the most common disorders observed in T2DM (Skomro et al., 2001).
Epidemiologic studies have reported that the prevalence of sleep apnea in diabetes
patients is around 50% (Frye et al., 2007).

Circadian Control of Sleep-wake Cycle, Melatonin and Diabetes
According to the two-process model proposed by Borbély 1982, the homeostatic
process (process S) is determined by the previous amount of sleep and wakefulness, in
which the sleep pressure is greatest at the beginning of sleep and gradually decreases
throughout this phase (Borbely, 1982). The circadian process (process C) organizes sleep
and wakefulness alternations over the 24 hours of the day. During wakefulness, little or
no homeostatic drive remains, but begins to accumulate and grows steadily during this
phase. For this reason, its strength is dependent upon the amount of time elapsed since
the last sleep period. When we are awake, the rising homeostatic sleep drive is opposed
by a circadian drive that activates wakefulness and influences this component until just
before sleep, when the circadian influence gradually declines (Beersma & Gordijn, 2007).
In situations such as sleep deprivation, the drive to sleep increases due to the accumulated
debt of sleep. Additionally, a decrease in sleep latency, and an enhancement of
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electroencephalogram (EEG) synchrony in NREM sleep are also observed (Borbely &
Achermann, 1999).
In addition to the homestatic drive influencing the circadian rhythmicity of the
sleep-wake cycle, the circadian process controls the timing and organization of sleep
through the Circadian System. This system aims to temporarily organize the
physiological processes of the body by specialized neural structures such as the
retinohypothalamic track, which is responsible for transmitting light signals from the
retina to the circadian master clock (the suprachiasmatic nucleus -SCN). The SCN
generates signals to the pineal gland to regulate melatonin (N-acetyl-5methoxytryptamine) production (Lewy et al., 1980; Scheer & Czeisler, 2005). In
response to light, the excitatory signal from the SCN and consequent suppression of
melatonin production are believed to be related to wakefulness promotion during the day.
In the dark phase, this inhibition is released and melatonin is produced, leading to sleep
promotion (Lewy et al., 1980; Scheer & Czeisler, 2005; Khullar, 2012). In this context,
the endogenous circadian melatonin rhythm is of great importance for synchronization of
the sleep-wake cycle (Nagtegaal, 2002).
Melatonin concentration in plasma begins to increase approximately 2 h before
habitual bedtime, it peaks around the first hours of the morning, and after waking,
decreases to levels close to those found during the day (Tzischinsky et al., 1993).
The Circadian System organization occurs in a hierarchical manner. The SCN
functions as a master oscillator and remains coupled with peripheral oscillators that are
present in nearly all cells, through nerve connections of the autonomic nervous system
and humoral signs (Brandstaetter, 2004). The major clock regulates the circadian rhythms
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in glucose, corticosteroids, leptin and cardiovascular systems through these connections
to the pancreas, liver, adrenal glands, adipose tissues and heart (Buijs et al., 2006). This
interaction allows synchronizations between the central and peripheral tissue clocks.
Moreover, various clock genes participate in the regulation of metabolic homeostasis
(Bass & Takahashi, 2010). For instance, it has been shown that when a clock disorder
occurs, it leads to disorders in glucose metabolism (Bass & Takahashi, 2010). Also,
feeding time can entrain intrinsic oscillation of clocks in liver cells, similar to what
occurs in central oscillators in the brain when entrained by light (Stokkan et al., 2001).
Additionally, experimental studies have suggested that gene expression rhythm
deregulation can cause metabolic dysfunction (Gatfield et al., 2009); and chronic
circadian misalignment might be correlated with metabolic and cardiovascular
dysfunction (Kohsaka & Bass, 2007; Ruger & Scheer, 2009; Scheer et al., 2009). These
findings support the understanding that circadian and metabolic systems are reciprocally
regulated (Young & Bray, 2007; Carneiro & Araujo, 2009; Bass & Takahashi, 2010;
Carneiro, 2012).
Studies have also found that the decreased melatonin levels in T2DM might be
related to the increased risk of developing T2DM (Peschke et al., 2006; Mantele et al.,
2012; McMullan et al., 2013). Associations between melatonin alterations and insulin,
glucose, lipid metabolism and antioxidant capacity have been reported (Nishida, 2005;
Robeva et al., 2008) and an experimental analysis has shown a relationship between
impaired melatonin levels and disturbances in insulin sensitivity that can be associated
with development of T2DM (Peschke et al., 2006). In addition, the use of exogenous

6

melatonin has been suggested as an adjunct to improve glucose control and diabetic
complications in T2DM (Garfinkel et al., 2011).

Physical Activity and the Sleep-wake Cycle
The benefits of physical activity for prevention and treatment of T2DM and
cardiovascular diseases are well known and are mainly related to the potential to reduce
insulin resistance in an inverse fashion (Waxman, 2004; Gill & Malkova, 2006; Ross &
Despres, 2009; Zuo et al., 2012). However, T2DM has been intensively associated with
sleep disorders (Knutson et al., 2006; Tasali et al., 2009; Plantinga et al., 2012), which
has been reported to be related to the decrease in physical activity (Nedeltcheva et al.,
2009a; Paparrigopoulos et al., 2010). Furthermore, a combination of low physical activity
and insufficient amount of sleep is also associated with insulin resistance (Zuo et al.,
2012). A study by Zuo et al., 2012, reported that adequate sleep duration together with
different types of physical activity may assist the decrease of insulin resistance and its
consequences (Zuo et al., 2012). Bromley et al. 2012, suggested that the decrease in
physical activity is one of the factors mediating the association between chronic
inadequate sleep with metabolic morbidity (Booth et al., 2012; Bromley et al., 2012).
Associations between sleep, physical activity, and insulin resistance include
reports showing inadequate sleep being related to excessive daytime sleepiness and
decreased physical functioning (Weaver et al., 1997). Also, it has been found that
physical activity can be decreased by sleep restriction, and improvement in sleep quality
can be seen after increasing physical activity (Nedeltcheva et al., 2009a; Paparrigopoulos
et al., 2010). Therefore, it has been proposed that one of the factors mediating the
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association of inadequate sleep and the increased incidence of metabolic morbidity is the
decrease in physical activity. However, many studies had based the sleep analysis on
subjective questionnaires that might be limiting the precision of the outcomes (Shephard,
2003; Lauderdale et al., 2008). Inconsistent results have been found on the association
between self recalled sleep duration and physical activity. Liu et al. 2000 (Liu et al.,
2000) and other authors (Ohida et al., 2001; Patel et al., 2008), found a positive
relationship between self-reported sleep and physical activity; while other researchers
reported a negative association (Chaput et al., 2008) or even no association between these
two variables (Imaki et al., 2002; Youngstedt et al., 2003; Patel et al., 2006).
Although studies have shown a relationship between physical activity and sleepwake cycle organization (Miyazaki et al., 2001; Buxton et al., 2003), we found no studies
on diabetes addressing the consequences of physical inactivity on this circadian control.
The influence of exercise on the circadian system is found when exercise is conducted
between the middle and end of the nocturnal phase, in which a phase delay is observed
(Miyazaki et al., 2001; Buxton et al., 2003). Conversely, phase advance is found when
exercise is performed six hours after awakening (Buxton et al., 2003). Van Reeth et al.,
1994, observed that physical exercise during night caused a clear phase delay of one to
two hours a day after starting an exercise protocol (Van Reeth et al., 1994). Changes were
also observed in melatonin and thyrotropin levels. The largest delays were found when
exercise was performed three to five hours before the minimum temperature (Van Reeth
et al., 1994). O'Connor and Youngstedt 1995, based on the hypothesis that a better
quality of sleep causes less tiredness during the day and more provision for physical
activity, supported that the quality of sleep of active people is better than inactive people
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(O'Connor & Youngstedt, 1995). Vuori et al., 1988, reported that sleep is improved when
exercise is introduced, and sedentary individuals are the ones that benefit the most (Vuori
et al., 1988).
Due to the growing source of evidence demonstrating a relationship between
physical activity and sleep, the American Society of Sleep Disorders reports physical
activity as a nonpharmacological therapeutic modality for the treatment of sleep disorders
(Shapiro & Flanigan, 1993; Youngstedt et al., 1997; Chasens et al., 2007).
Although exercise is cited as one of the major synchronizers in humans; it is not
known for certain which mechanisms are responsible for this synchronization. Some
researchers suggest, through experiments with rodents, that there is a participation of
secondary neural pathways sending information to the SCN. The thalamic intergeniculate
leaflet and raphe nuclei are part of the main pathways proposed, transmitting information
about non-photic stimuli to the SCN (Vrang et al., 2003; Yannielli & Harrington, 2004).
However, additional studies are needed to further describe specific physical activity
parameters, such as intensity, duration, if accompanied by light or not, and what
population would benefit from the relationship between the increase in physical activity
level and the organization of the sleep-wake cycle.

Purpose of the Study
The risk of microvascular complications in patients with type 2 diabetes may be
reduced by approaches that focus on maintaining good glycemic control (Chiasson et al.,
2003; Gaede et al., 2003). The American Diabetes Association recommends maintaining
HbA1c levels less than 7% as studies have shown that this approach reduces
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microvascular complications due to diabetes (American Diabetes Association, 2010), and
also reduces myocardial infarction in cases when metformin is used in overweight
patients with diabetes (UK Prospective Diabetes Study Group, 1998a). Therefore, it is of
great importance to address any action that reduces glycemic control such as inadequate
sleep. Studies that address sleep-wake cycle are imperative to identify what parameters of
this cycle may be influencing sleep in patients with diabetes, while also helping to
recognize which approaches can be administered for sleep improvement in this
population. Therefore, the aim of this study was to analyze the sleep-wake cycle in
subjects with T2DM and compare it to healthy controls using the nonparametric
approach.
Additionally, since there seems to be a complex interaction involving alterations
in melatonin production, circadian rhythm disturbances, impaired insulin and glucose
metabolism and T2DM; it is important to further investigate alterations in the sleep-wake
cycle and melatonin to identify the steps that can be taken to minimize the consequences
of these disturbances, and thus assist in improving the health of this population.
Therefore, the aim of this study was also to assess the changes in the circadian and
homeostatic control of the sleep-wake cycle in T2DM and correlate it with melatonin
concentration.

Approaches of the Study
The analysis of the sleep-wake cycle on T2DM needs to be explored. To our knowledge,
this is the first study to further discuss the sleep-wake cycle in T2DM applying the
nonparametric methodological approach, and base the analysis on the Two-process
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Model Theory to assess the circadian and homeostatic controls; furthermore it is the first
study to correlate these variables with melatonin concentration in diabetic subjects. The
rest-activity rhythm was assessed through actigraphy, using the Actiwatch 2® from
Philips. The raw activity counts were extracted from this device and used for analysis of
the nonparametric approach. Additionally, sleep-wake variables were obtained from
Respironics Actiware 5.70.1 software. The nonparametric methodological approach of
the rest-activity rhythm assessment, previously reported by Van Someren et al., 1996, is
composed of three main variables: interdaily stability (IS), intradaily variability (IV) and
amplitude (AMP). This approach was performed in our study and its discussion is in
Chapter 2 of this dissertation. The analysis on the Two-Process Model Theory, to further
analyze the rest-activity rhythm, and the correlation with salivary melatonin levels is in
Chapter 3 of this dissertation.

Significance of the Study
According to the Centers for Disease Control and Prevention, sleep complaints have a
high incidence rate in the United States diabetic population, and individuals with diabetes
are more likely to have sleep impairments when compared to controls. Additionally, sleep
disorders have been both identified as a risk factor for developing T2DM, as well as
associated with worsening the diabetes condition. Authors have suggested that irregular
sleep-wake cycle patters and short and long sleep may enhance dysfunction in the
glucose metabolism. However, little is known about the circadian and homeostatic
control of the sleep-wake cycle in this population. The results of this study contribute to
the understanding of these parameters and identify specific disturbances of the circadian
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and homeostatic control of the sleep-wake cycle. We believe that with further analysis on
the sleep-wake cycle in type 2 diabetics, it will be possible to better identify therapeutic
procedures that might help to achieve a better sleep-wake cycle organization, better sleep
parameters and ultimately, a better glycemic control in type 2 diabetics.

12

CHAPTER TWO
A NONPARAMETRIC METHODOLOGICAL ANALYSIS OF SLEEP-WAKE CYCLE
IN TYPE 2 DIABETES

By 1Paula Regina Aguiar Cavalcanti, DSc, PT; 1,2Lee Berk, DrPH, MPH, CLS; 3Noha
Daher, DrPH, MSPH; 4Tania Campus, Phd, PT; 4Araujo, John, Phd, MD; 1Jerrold S.
Petrofsky, Phd, J.D.; 1Everett Lohman, DSc, PT, OCS

1

Dept. of Physical Therapy, School of Allied Health Professions, Loma Linda University

2

Dept. Pathology and Humans Anatomy, School of Medicine, Loma Linda University

3

Dept. of Computing, Research and Statistics, School of Allied Health Professions, Loma

Linda University
4

Neurobiology and Biological Rhythm Laboratory, School of Psychobiology, Federal

University of Rio Grande do Norte

13

Abstract
Type 2 diabetics have a high incidence of sleep impairments. Since sleep
deficiency can be associated with impaired glycemic control, studies of the sleep-wake
cycle in diabetics are important in identifying which parameters of the cycle may
influence sleep. The purpose of this study was to analyze the sleep-wake cycle of type 2
diabetics and compare them to healthy controls using the nonparametric analytic
approach. Twenty-one diabetics and 21 healthy subjects matched for gender and age were
recruited to participate in the study. Subjects were assessed by the Beck’s Depression
Inventory (BDI), the Apnea Risk Evaluation System (ARES) questionnaire, hemoglobin
A1c (HbA1c) and actigraphy. The nonparametric methodological approach of restactivity rhythm assessment is composed of three main variables: interdaily stability (IS),
intradaily variability (IV) and amplitude (AMP). Data were analyzed using the
Independent t-test, Mann-Whitney U test, and Spearman's correlation. Type 2 diabetics
subjects demonstrate lower IS (p=.03), higher IV (p=.046) and lower rhythm amplitude
(p=.02) when compared to healthy controls. Also, there was a positive correlation
between IS and most active 10 hr (M10)) in the average of 24 hours pattern (r =.44;
p=.046) in the diabetes group and a negative correlation between IV and M10 in the
control group (r =-.57; p=.007). These data together suggest that type 2 diabetes mellitus
(T2DM) exhibits a dysfunction in the sleep-wake cycle due to alterations in the circadian
function as well as in the homeostatic capacity to maintain sleep; mainly characterized by
less consistency across days of the daily circadian signal, higher rhythm fragmentation
and lower rhythm amplitude. Future approaches may be developed considering the
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influence of circadian glucose variations throughout the day and meal times on the
coupling of the rest-activity rhythm to zeitgeber and rhythm fragmentation.

Key words: actigraphy, interdaily stability, intradaily variability, amplitude, most active
10 h, least active 5h
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Introduction
There are approximately 25.8 million individuals with diabetes in the United
States; of whom 90% to 95% are classified as type 2 diabetes mellitus (T2DM)
(Department of Health and Human Services, 2011). Among the common studied risk
factors for T2DM include: unhealthy diet, smoking, physical inactivity, obesity, and
alcohol abuse (American Diabetes Association, 2003; van Dam, 2003). Furthermore, the
Centers for Disease Control and Prevention have reported that sleep complaints have a
high incidence rate in the United States diabetic population, and individuals with diabetes
are more likely to have sleep impairments when compared to controls (Plantinga et al.,
2012).
The main connections between type 2 diabetes and poor sleep have been
attributed to impairments in glucose metabolism and circadian variation of hormone
levels (Gottlieb et al., 2005; Van Cauter et al., 2007a; Spiegel et al., 2009). Glucose
tolerance and insulin secretion are adjusted according to the sleep-wake cycle (Van
Cauter et al., 1991). The homeostasis of normal glucose metabolic process is directly
influenced by inadequate sleep through disruption of circadian rhythms, clock gene
function and variation in autonomic nervous system activity (Laposky et al., 2008;
Gangwisch, 2009). Moreover, glucose consumption is greatest during wake and lowest
during non-rapid eye movement (NREM) sleep; also glucose metabolism expresses a
diurnal pattern with variations in glucose tolerance throughout the day (Van Cauter et al.,
1991; Scheen et al., 1996).
The Circadian System aims to temporally organize the physiological processes of
the body by specialized neural structures such as input pathways, responsible for
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transmitting signals such as light to the circadian master clock (the suprachiasmatic
nucleus -SQN) (Dijk & von Schantz, 2005). This major clock regulates the circadian
rhythms in glucose, corticosteroids, leptin and cardiovascular systems through the
autonomic nervous system and humoral signs to the pancreas, liver, adrenal glands,
adipose tissues and heart (Buijs et al., 2006). This interaction allows synchronizations
between the central and peripheral tissue clocks. Moreover, various clock genes
participate in the regulation of metabolic homeostasis (Bass & Takahashi, 2010). For
instance, it has been shown that when a clock disorder occurs, it leads to disorders in
glucose metabolism (Bass & Takahashi, 2010). Also, feeding time can entrain intrinsic
oscillation of clocks in liver cells, similar to what occurs in central oscillators in the brain
when entrained by light (Stokkan et al., 2001). These previous findings support the
understanding that circadian and metabolic systems are reciprocally regulated (Young &
Bray, 2007; Carneiro & Araujo, 2009; Bass & Takahashi, 2010; Carneiro, 2012).
The risk of microvascular complications in patients with T2DM may be reduced
by approaches that focus on maintaining a good glycemic control (Chiasson et al., 2003;
Gaede et al., 2003). The American Diabetes Association recommends maintaining
HbA1c levels less than 7% as studies have shown that this approach reduces
microvascular complications due to diabetes and also reduces myocardial infarction in
cases when metformin is used in overweight patients with diabetes (UK Prospective
Diabetes Study Group, 1998a, 1998b; American Diabetes Association, 2012). Therefore,
it is of great importance to address any action that reduces glycemic control such as
inadequate sleep. Studies that address sleep-wake cycle are imperative to identify what
parameters of this cycle may be influencing sleep in patients with diabetes, while also
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helping to recognize which approaches can be administered for sleep improvement in this
population. Therefore, the aim of this study was to analyze the sleep-wake cycle in
subjects with T2DM and compare it to healthy controls using the nonparametric
approach.

Material and Methods
Sample
Twenty-five diabetic subjects (age range from 49 to 78 years old) were recruited
for the study. The control group consisted of 21 healthy individuals matched for gender
and age with the diabetes group. The study inclusion criteria consisted of diagnosis of
diabetes for more than a year. Exclusion criteria were diagnosis of obstructive sleep
apnea, neurological comorbidities such as Parkinson’s and Alzheimer’s disease, use of
antidepressant or any other drug that may affect alertness or drowsiness (e.g. melatonin,
antipsychotics, antidepressants, benzodiazepines, muscle relaxants), depression (a score
of 17 and over was considered an indicator of the presence of the clinically significant
depressive symptoms assessed by Beck’s Depression Inventory), improper use of the
actiwatch, incomplete sleep diary and important change in social routine during the week
of data collection. A total of four diabetic subjects were excluded from the study due to
incorrect use of the actiwatch, report of sleep apnea and severe depression (according to
Beck’s Depression Inventory).

Procedures
The study was approved by Loma Linda University Institutional Review Board
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and all subjects were informed on the procedures of the investigation and signed an
informed consent. The following demographic data were assessed: gender, age, weight
and height, from which we calculated body mass index (BMI) (weight in kilograms
divided by height in meters squared). The blood level of hemoglobin A1c (HbA1c) was
measured using DCA VantageTM Analyzer (Siemens®, Malvern, PA, USA). HbA1c is a
gold standard for monitoring glycemic control, and it reflects glucose levels over the past
2 to 3 months (International Expert Committee, 2009; American Diabetes Association,
2012). The study sample was classified as good (HbA1c < 7.5%) or poor glycemic
control (HbA1c ≥7.5%) (Hartemann-Heurtier et al., 2001; Juarez et al., 2012). Duration
of time since the diagnosis of diabetes and type of treatment for T2DM were also
recorded.
Depression was assessed using the Beck’s Depression Inventory (BDI), consisting
of 21 questions that evaluate how severe is classified the depressive symptoms. The total
score is a sum of all questions and range from 0-63. It is classified in four categories:
“These ups and downs are considered normal” (1-10 points); “Mild mood disturbances”
(11-16 points); “Borderline clinical depression” (17-20 points); “Moderate depression”
(21-30); “Severe depression” (31-40 points); and “Extreme depression” (over 40 points)
(Richter et al., 1998; Contreras S, 2004).
Subjects were screened for risk of obstructive sleep apnea (OSA) through Apnea
Risk Evaluation System (ARES) questionnaire. This instrument considers demographic
characteristics, diseases that are associated with risk for OSA (i.e., high blood pressure,
heart disease, diabetes, or stroke), Epworth sleepiness scale, and a five-scale response to
the frequency rating for snoring, waking up choking, and breathing difficulties during
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sleep. Scoring between 4 or 5 is considered low risk for OSA, 6 to 10 high risk and 11 or
more as very high risk (Levendowski D. J OR, 2007).
Rest-activity rhythm was measured in subjects’ own homes using actimetry
through Actiwatch 2 (Philips Respironics®, Andover, MA, USA). Actimetry consists of
a non-invasive method for the indirect evaluation of the sleep-wake cycle and it is
recognized by the American Academy of Sleep Medicine as helpful adjunct to clinically
assess sleep disorders (American Sleep Disorders Association, 1995). The device was
placed on subjects' non-dominant wrist for 7 days along with an explanatory pamphlet for
the actiwatch and a sleep log. Subjects were also instructed to maintain their normal daily
routine. Recordings per minute for six complete days and seven nights were used for the
analysis. The Actiwatch 2 has a button to mark events and subjects were asked to press
the button when they went to bed at night and when they got up in the morning; also, it
has an ambient light monitor to assess the amount to Lux the participant has been
exposed to. Subjects were asked not to remove the device from their wrist during the
study week. Data on sleep and activity levels were primarily calculated using the
Respironics Actiware 5.70.1 software (Philips Respironics®, Andover, MA, USA). The
raw activity counts were extracted and analyzed by nonparametric approach (Van
Someren et al., 1997a). This method of rest-activity circadian rhythm assessment is
composed of three main variables: interdaily stability (IS)- shows how is the union
between the rest-activity rhythm and the Zeitgeber (external time signaling stimuli)
express the strength of coupling between the rest-activity rhythm and Zeitgebers;
intradaily variability (IV) – representing the transitions periods between rest and activity
representing fragmentation of periods of rest and activity; and amplitude (AMP)
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(difference between least active 5 h (L5) and most active 10 h (M10)) in the average of
24 hours pattern, described previously by Van Someren et al., 1997 (Van Someren et al.,
1997a). The calculations of each circadian variable were performed as follow:
IS is described as ratio between the variance of the average 24-hour pattern
around the mean and the overall variance. The IS considers individual days to quantify
how similar the activity patterns are. Higher values are indicative of rhythm stability, and
it has been reported to be around 0.6 in healthy adults (Huang et al., 2002; Calogiuri et
al., 2013).
The formula for IS is:
𝑝

IS=

𝑁 ∑ℎ=1(x̄h−x̄)2
2
𝑝 ∑𝑁
𝑖=1(𝑋i−x̄)

Where N is the total number of data, p is the number of data per day; x̄h are the
hourly means, x̄i represent the individual data points, and x̄ represents the mean of all
days.
The IV ranges from 0 to 2 and studies have shown that scores <1 are found in
healthy adults. Rhythm fragmentation is characterized by higher values of IV. This
variable is calculated as the ratio of the mean squares of the difference between
successive hours and the mean squares around the grand mean, as shown below (Van
Someren et al., 1997a):
𝑁 ∑𝑁 (𝑋i−𝑋i-1)2

IV= (𝑁−1)𝑖=2∑𝑁

𝑖=1(x̄−𝑋i)

2
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Data Analysis
Data analysis was performed using SPSS 21.0 software (Armonk, NY, USA). The
Kolmogorov-Smirnov test was used to examine the distribution of the continuous
variables. The independent t-test was used to compare groups in regards to mean of age,
BMI, ARES score and BDI, as well as, the differences in circadian variables, which were
followed by ANCOVA to control for risk of OSA, mean light exposition per minute and
average of all light in Lux. The Pearson’s correlation test was applied to examine the
intra-group correlation among circadian variables and HbA1c. The chi-square Fisher’s
exact test was used to compare proportions of males and females by group. Comparisons
between good control and poor control were assessed using Mann-Whitney U test. The
level of significance was set at p<.05.

Results
The subjects’ characteristics are shown in Table 1. There were no significant
differences between the diabetic and control groups in terms of gender, weight, height
and BMI. In the diabetic group, the mean time since diagnosed with diabetes was 7.8±9.6
years. The HbA1c level varied from 5.1 to 10.7; however, there was no significant
difference in duration of diagnosis between good and poor controls. There was no
significant difference in BDI score between groups (Diabetic 5.8±5.8 vs. Control 3.5±3.4;
p=.13). Regarding the risk for sleep apnea, there was a significant difference between
groups (5.8±2.7 vs. 3.4±2.7; p=.009). However, risk for OSA did not meet the modeling
criterion for confounding when analyzing the differences between groups and the
circadian variables.
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Table 1 - Mean±SD of subjects’characteristics according to group.
Diabetic
Group
21

Control
Group
21

38.1
61.9

42.9
57.1

.50

59.0 ± 8.6

59.5 ± 8.5

.68

79.0± 15.3

.33

1.7 ± .1

.91

27.6 ± 7.2

28.8± 4.3

.21

High blood pressurea (%)

85.7

14.3

<.01*

Duration of disease (years)

11.7 ± 9.6

Variables
n
Gender a (%) Male
Female
Ageb (years)
Weightb (Kg)
Heightb (m)
b

2

BMI (kg/m )

b

HbA1c (%)

77.0 ±
15.0
1.7 ± .1

p
value

7.7 ± 1.4

Diabetes treatment (%)
Oral drug
Insulin
n, number of subjects per group
a
Fisher’s test comparisons
b
Independent test comparisons
*significant difference (p<.05)

61.9
38.1

Compared to controls, the diabetic group showed a significant decrease in IS
(.37±.04 vs. .40±.07; p=.03) (Figure 1, A) and a significant increase in IV (.50±.05 vs.
.45±.12; p=.046) (Figure 1, B). Additionally, diabetic subjects were significantly less
active than healthy controls, as shown by the result of M10 (298.3±72.2 vs. 370.1±114.0;
p=.02) (Figure 1, C) and during the least 5 hours of activity, diabetic subjects had higher
active counts when compared to controls (17.6±8.3 vs. 12.2±5.7; p=.02) (Figure 1, D).
Calculation from M10 and L5 demonstrated a significant lower amplitude of the restactivity rhythm for the diabetic group (281.0±70.4 vs. 349.3±104.6; p=.02) (Figure 1, E).
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There was a positive correlation between IS and M10 (ρ=.44; p=.046) in the
diabetic group and a significant negative correlation between IV and M10 in the control
group (ρ=-.57; p=.007). However, there was no significant correlation between IV and
M10 in the diabetic group and IS and M10 in the control group.
B

A

*

*

C

E
*

*

D
*

Figure 1 –A, mean±SD interdaily stability; B, mean±SD intradaily variability; C,
mean±SD amplitude of rest-activity rhythm; D, mean±SD of most active 10 hours; E,
mean±SD of least active 5 hours of diabetes and control group. An asterisk (*) indicates
that the group differs on this variables in the Student’s t-test, p<.05.
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Figure 2A illustrates the actogram of a healthy individual, in order to compare it
with the actogram of a diabetic subject. The actogram in Figure 2B shows high instability
between days. The subject in Figure 2C shows low amplitude of the activity rhythm and
Figure 1D illustrates fragmentation in a subject with frequent records of periods of rest
and activity. In regards to HbA1c levels in good and poor controls, there were no
significant differences in the circadian variables.
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A

B

Figure 2: Actograms showing activity thresholds (vertical bar) divided into light phase
(6:00 a.m. to 5:45 p.m.) and dark phase (5:45 p.m. to 6:00 a.m.), of (A) a control subject;
(B) a diabetic subject showing high instability between days.
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C

D

Figure 2: Actograms showing activity thresholds (vertical bar) divided into light phase
(6:00 a.m. to 5:45 p.m.) and dark phase (5:45 p.m. to 6:00 a.m.), of (C) a diabetic subject
showing low rhythm amplitude, and (D) a diabetic subject showing high fragmentation.
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There were no significant differences in the sum of all light exposition (Lux
multiplied by minute) and average of all valid light (Lux) from the start time to the end
time of active interval between groups, however, the diabetic group was exposed to less
amount of light (424654.1±263551.6 vs. 478923.9±414253.4; p=.61). Also, the amount
of all valid light for the diabetic group was less than the control group (477.5±297.2 vs.
531.7±431.1; p=.64). Moreover, poor controls were significantly less exposed to light per
minute than good controls (548322.2±257660.0 vs. 288619.2±203310.3; p=.02); and
there was a significantly less amount of all valid light in Lux for the poor control, when
compared to the good control (617.7±298.0 vs. 323.2±217.2; p=.02) (Figure 3).

A

B

*

*

Figure 3: A, mean±SD light exposition (Lux multiplied by minute); and B, mean±SD
average of all valid light (Lux) from the start time to the end time of active interval
according to group. An asterisk (*) indicates that the group differs on this variables in the
Mann-Whitney’s test, p<.05.

Discussion
The present study examined the sleep-wake cycle variations on T2DM using a
non-parametric approach. The findings revealed that T2DM individuals demonstrate
lower IS, indicating a less consistency across days of the daily circadian signal; higher
IV, showing greater variability within each 24-hour period; and lower peak activity
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levels, indicating lower amplitude compared to healthy, age matched subjects. These data
together suggest that T2DM exhibit a dysfunction in the sleep-wake cycle due to
alterations in the circadian function as well as in the homeostatic capacity to maintain
sleep. To our knowledge, this is the first study to assess the sleep-wake cycle on T2DM
using the nonparametric approach.
Reports on the non-parametric approach on the analysis of the sleep-wake cycle
have been previously published in healthy individuals, Alzheimer and Parkinson’s
disease but to date no published studies have used this approach in T2DM subjects (Van
Someren et al., 1996; Van Someren et al., 1997b; Whitehead et al., 2008). For this
reason, comparisons on circadian variables in this study were mainly examined
indirectly.
Van Someren et al. (1996) found low IS in Alzheimer patients especially in those
that were institutionalized. Our findings on T2DM also showed decrease in this circadian
variable. The IS is indicative of how similar the activity pattern is expressed on different
days. It can indicate how consistent the daily circadian signal is across days; also,
revealing the strength of its coupling to stable zeitgebers. Typically, high values are
indicative of a more stable rhythm, and it was found to be around 0.6 for healthy adults
(Van Someren et al., 1997b; Calogiuri et al., 2013). Our finding is in agreement with this
result as we observed lower values in IS for the diabetic group (.37±.04) compared to
controls (.42±.07) (Van Someren et al., 1997b).
In regards to IV, the diabetic group showed significantly higher values when
compared to controls and higher values of IV are indicative of more fragmented rhythm.
Similar results were observed in Parkinson’s disease. Whitehead et al. (2008) reported
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that on the Parkinson’s group, it was found a more fragmented rest-activity rhythm with
constants transitions from high to low periods of activity. Authors reported that the restactivity rhythm is less predictable in these patients. In regards to T2DM, studies have
shown that nocturia is a significant variable that is positively correlated with difficulty to
maintain sleep (Lamond et al., 2000) and it might as well contribute to increase IV in the
diabetic population.
Whitehead et al. (2008) also found lower peak of physical activity and lower
rhythm amplitude in subjects with Parkinson’s disease. Authors suggested that this
finding could be related to the motor impairment found in this population. Previous
analysis on stroke patients also revealed alteration on the amplitude of the sleep-wake
cycle that might as well impair the quality of life of these individuals (Cavalcanti, 2012;
Cavalcanti, 2013). Motor alterations on stroke patients could be influencing the
expression of this variable (Cavalcanti, 2012). Similarly, we observed lower levels of
physical activity and low rhythm amplitude in the diabetic group. This finding could be
related to the increased sedentary activity commonly found in these individuals.
Van Someren et al. (1996) reported a strong association between IS and IV with
daytime activity. They explained that this association does not result from the
mathematical model, but from the organized pattern of the high levels of daytime activity
which lead to an organized circadian rhythm. Moreover, as activity level functions as an
output and as an input of the circadian timing system, Van Someren et al. (1996)
suggested that daytime activity level is of great importance in circadian rest-active
disturbances and might as well be one of the causes for the rhythm disturbances in the
Alzheimer population. These findings are in line with our results in which IS showed

30

positive association with daytime activity in the diabetic group. However, more studies
are needed to test if increasing the amplitude of the activity rhythm would result in more
regulation of the sleep-wake cycle.
Actigraph studies on T2DM subjects revealed that sleep-wake cycle irregularities
are more frequent in these individuals than in the healthy controls. Tsujimura et al. (2009)
reported higher scores of night activity in the diabetic group when compared to controls
(Tsujimura et al., 2009). Additionally, they reported that higher fasting plasma glucose
and HbA1c values were positively correlated with pronounced sleep and circadian
rhythm disturbances. Our study also found higher activity level in the diabetic group
during night time (measured by L5, related to the least 5 hours of activity, night activity);
however, we did not find significant relationships between HbA1c and the circadian
variables. Nakanishi-Minami et al. (2012) reported that T2DM subjects tended to go to
bed later and wake up later; and had higher daytime sleepiness compared to controls
(Nakanishi-Minami et al., 2012). These authors suggested that irregular sleep-wake cycle
patters and short and long sleep may enhance dysfunction in the glucose metabolism.
It is well known that meal time exert influence in the circadian regulation
(Mendoza, 2007). A variety of behavioral and physiological activities are entrained by
food, as it is considered to be a potent synchronizer of peripheral clocks (Hara et al.,
2001; Stephan, 2002; Mendoza, 2007; Carneiro et al., 2012). For instance, researchers
have demonstrated that the use of glucose only as nourishment is able to synchronize not
only the rest-activity rhythm but also the temperature rhythm in rats (Hara et al., 2001;
Stephan, 2002; Mendoza, 2007; Carneiro et al., 2012). Wu et al. (2012) in a study with
induced T2DM rats, observed that daytime restricted feeding condition shows a more
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preeminent effect on the reentrainment of circadian rhythm in the T2DM rats; leading
them to suggest that the circadian system in diabetics is unstable and more easily shifted
by feeding stimuli (Wu et al., 2012). Studies also have shown that disruptions on
circadian rhythms can provoke the development of metabolic disorders, including obesity
and T2DM (Turek et al., 2005; Woon et al., 2007). Furthermore, alterations on the
rhythm of glucose tolerance have been reported even in first-degree relatives of patients
with T2DM (Boden et al., 1999). However, it is not clear whether this alteration exerts
influence on the sleep-wake cycle and which mechanisms would be related. Our study
has not found significant relationships between HbA1c and the circadian variables using
the nonparametric method, perhaps due to the small sample size. More research is
required in order to examine associations between glycemic control and the sleep-wake
cycle. We believe that these studies should include analysis of the glucose variation
throughout the day, as HbA1c reflects the overall glycemic control for the past 2 to 3
months and not the variances occurred during the specific days of analysis. Additionally,
studies should record subjects’ meal time, as these variables might exert influence mainly
on IS and IV, and could further explain the alterations found in this study.
In regards to the light exposition, we have examined the amount of light the
subjects were exposed to throughout the week. Studies on the influence of light in
circadian rest-activity rhythm regulation have shown that sessions of bright light during
the day can increase IS, and decrease IV (Van Someren et al., 1997a). The association
between IS and daytime light exposition has also been reported (Van Someren et al.,
1996). Although our study did not found differences between groups in light exposition
(Lux multiplied by minute) and average of all valid light (Lux); the diabetic group was
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exposed to less amount of light, and had lower values for all valid light during the active
phase. Moreover, it has been previously reported that ophthalmic diseases, such as
cataract, diabetes retinopathy, and glaucoma might affect photic input to the circadian
system (Jean-Louis et al., 2008). Therefore, it is possible that the presence of unknown
retinopathy or other ophthalmic disease may have influenced the strength of the coupling
of the rhythm to this environmental Zeitgeber. When analyzing differences between good
and poor glycemic control, it was observed that the poor control was exposed to
significant less amount of light. We recommend for futures studies to perform a clinical
assessment for ophthalmic disease on T2DM in order to better assess the influence of
light on these circadian variables.
Some limitations should be considered in this study. First, this is an observational
study and no causality can be assumed; moreover, the lack of differences between good
and poor control and associations with HbA1c with the circadian variables may be a
function of the limited power of the diabetes sample because of the small sample size.

Conclusions
In summary, we have shown that the sleep-wake cycle is disturbed in T2DM
when compared to healthy controls and it is mainly characterized by lesser consistency
across days of the daily circadian signal, higher rhythm fragmentation and lower rhythm
amplitude. Futures approaches may be developed to better investigate which mechanisms
are involved in this sleep-wake cycle deregulation in T2DM, also considering the
influence of circadian glucose variations throughout the day and meal times on the
coupling of the rest-activity rhythm to zeitgeber and rhythm fragmentation.
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Abstract
The purpose of this study was to assess the changes in the circadian and
homeostatic control of the sleep-wake cycle in type 2 diabetes mellitus (T2DM) and
correlate the findings with salivary melatonin levels. The study cohorts were 21 subjects
with a diagnosis of T2DM of more than one year and 21 healthy subjects age and gender
matched. Subjects were assessed by the Beck’s Depression Inventory (BDI), the Apnea
Risk Evaluation System (ARES) questionnaire, hemoglobin A1c (HbA1c), actigraphy
and salivary melatonin levels. Melatonin levels at bed time were significantly lower in
diabetic subjects than healthy controls (11.7±7.2 pg/mL vs. 24.1±10.8pg/mL; p<.01).
Actigraphic analysis during the wake phase showed that diabetic subjects had lower
levels of activity (p=.02). Additionally, there was a significant decrease in sleep duration
(p=.03), efficiency (p=.02); and higher activity counts during the sleep phase (p=.02) in
the diabetic group when compared to controls. Sleep efficiency was significantly
correlated with melatonin collected two hours before bed time (r=.61; p=.047).
Additionally, there were significant inverse relationships between melatonin collected at
two hours before bed time and latency (r=-.87; p=.001), wake after sleep onset (r =-.69;
p=.02) and nocturnal activity (r =-.67; p=.03). Latency was inversely correlated with
melatonin collected at bed time (r =-.69; p=.02). These composite findings suggest that
T2DM presents disturbances in the homeostatic drive to sleep. Moreover, in addition to
lower melatonin levels, the decrease in the amplitude of the activity rhythm may also be
involved in circadian alterations of the sleep-wake cycle.

Key words: type 2 diabetes, sleep-wake cycle, melatonin, HbA1c, actigraphy
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Introduction
Among the American diabetic population, sleep complaints are of high incidence
and importance (Plantinga et al., 2012). Sleep disturbances are related to an increased risk
of developing chronic systemic conditions, such as hypertension (Gangwisch et al.,
2006), obesity and cardiovascular disease (Gangwisch et al., 2005; Gangwisch et al.,
2006). Furthermore, sleep disorders have been both identified as a risk factor for
developing T2DM, as well as associated with worsening the diabetes condition (Knutson
et al., 2006; Tasali et al., 2009).
Sleep-wake cycle disturbances in T2DM have been previously reported (Trento et
al., 2008; Nakanishi-Minami et al., 2012; Rajendran et al., 2012). Alterations on daytime
sleepiness, sleep duration, sleep efficiency, onset latency and decreased quality of sleep
have been described (Trento et al., 2008; Nakanishi-Minami et al., 2012; Rajendran et al.,
2012). Despite the literature addressing the sleep disturbances, little is known about the
involvement of the circadian and homeostatic controls and the extension of synchronizers
influence, such as melatonin, on these processes. The organization of the sleep-wake
cycle, according to the two-process model proposed by Borbély (Borbely, 1982), is
composed of homeostatic and circadian processes. The homeostatic process (process S) is
determined by the previous amount of sleep and wakefulness, in which the sleep pressure
is greatest at the beginning of sleep and gradually decreases throughout this phase. The
circadian process (process C) organizes sleep and wakefulness alternations over the 24
hours of the day. Its control is expressed by the Circadian System (Dijk & von Schantz,
2005). This system aims to temporally organize the physiological processes of the body
by specialized neural structures such as the retinohypothalamic track, which is
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responsible for transmitting light signals from the retina to the circadian master clock (the
suprachiasmatic nucleus -SCN). The SCN generate signals to the pineal gland to regulate
melatonin (N-acetyl-5-methoxytryptamine) production (Lewy et al., 1980; Scheer &
Czeisler, 2005). In response to light, the excitatory signal from the SCN and consequent
suppression of melatonin production are believed to be related to wakefulness promotion
during the day. In the dark phase, this inhibition is released and melatonin is produced,
leading to sleep promotion (Lewy et al., 1980; Scheer & Czeisler, 2005; Khullar, 2012).
In this context, the endogenous circadian melatonin rhythm is of great importance for
synchronization of the sleep-wake cycle (Nagtegaal, 2002).
Melatonin concentration in plasma begins to increase approximately 2 h before
habitual bedtime, it peaks around the first hours of the morning and after waking,
decreases to levels close to those found during the day (Tzischinsky et al., 1993).
Studies have found decreased melatonin levels in T2DM and it has been proposed
that melatonin deficiency may be related to increased risk of developing T2DM (Peschke
et al., 2006; Mantele et al., 2012; McMullan et al., 2013). Associations between
melatonin alterations and insulin, glucose, lipid metabolism and antioxidant capacity
have been reported (Nishida, 2005; Robeva et al., 2008) and an experimental analysis has
shown a relationship between impaired melatonin levels and disturbances in insulin
sensitivity that can be associated with development of T2DM (Peschke et al., 2006). In
addition, the use of exogenous melatonin has been suggested as an adjunct to improve
glucose control and diabetic complications in T2DM (Garfinkel et al., 2011).
Since there seems to be a complex interaction involving alterations in melatonin
production, circadian rhythm disturbances, impaired insulin and glucose metabolism and
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T2DM; it is important to further investigate alterations in the sleep-wake cycle and
melatonin to identify the steps that can be taken to minimize the consequences of these
disturbances, and thus assist in improving the health of this population. Therefore, the
aim of this study was to assess the changes in the circadian and homeostatic control of the
sleep-wake cycle in T2DM and correlate it with melatonin concentration. To our
knowledge, this is the first study to further discuss the sleep-wake cycle in T2DM based
on the two-process model to assess the circadian and homeostatic controls; furthermore it
is the first study to correlate these variables with melatonin concentration in diabetic
subjects.

Materials and Methods
Sample
The sample consisted of 25 subjects with diagnosis of T2DM for more than a year
and 21 healthy controls matched for gender and age. The exclusion criteria consisted of:
Obstructive sleep apnea (OSA), neurological comorbidities such as Parkinson’s and
Alzheimer’s disease, use of antidepressant or any other drug that may affect alertness or
drowsiness (e.g. melatonin, antipsychotics, antidepressants, benzodiazepines, muscle
relaxants), depression (assessed by Beck's Depression Inventory as at least having
“borderline clinical depression”), incorrect use of the actimeter and report of important
routine changes while enrolled in the study. Four diabetics were excluded from the study
due to improper use of actimeter, classification of “severe depression” by the Beck's
Depression Inventory, and self report of sleep apnea.
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Procedures
The Loma Linda University Institutional Review Board reviewed and approved
the present study. All participants received proper information on the procedures
involved in the study and signed the informed consent. Variables measured included:
Gender, age, body mass index (BMI) (calculated based on weight in kilograms divided
by height in meters squared) and high blood pressure. In addition, the diabetic group was
assessed on duration of the diabetes diagnosis, presence of visual complaint, type of
diabetes treatment (oral drug or insulin) and glycemic control through hemoglobin A1c
(HbA1c) level.
According to the Center for Disease Control and Prevention, the level of HbA1c <
7.5% is defined as good glycaemic control, a level of HbA1c ≥7.5% to ≤9% is considered
fair glycemic control, and poor control is classified when HbA1c> 9% (HartemannHeurtier et al., 2001). The blood concentration of hemoglobin A1c (HbA1c) was
measured using the DCA VantageTM Analyzer (Siemens®, Malvern, PA, USA). For
analysis purposes, the diabetic group was classified as good (< 7.5%) and fair-poor
controls ( ≥7.5%).
Subjects were screened for risk of OSA through apnea risk evaluation system
(ARES) questionnaire. The questionnaire consists of 5 sections including: 1)
demographic data, 2) diagnosis of diseases associated with risk for OSA (i.e., high blood
pressure, heart disease, diabetes, or stroke), 3) sleepiness, and 4) frequency of snoring or
waking up choking, and 5) having been told about stop breathing during sleep. Scores
were classified as low, high and very high risk for OSA. Scoring between 4 and 5 is
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considered low risk, 6 to 10 high risk and 11 or more, very high risk (Levendowski D. J
OR, 2007).
Eleven subjects from the diabetic group and ten subjects from the control group
were selected to perform the melatonin analysis. Melatonin was assessed through saliva.
The melatonin collection was collected two hours before bed time, immediately before
bed time and as wake up in the following morning. In order to analyze melatonin, we
used amber-colored vials and the samples were shipped to Salimetrics® (State College,
PA, USA) for analysis. A pamphlet with instructions of how to perform the salivary
collection was given to subjects including: Collecting saliva in a dim light place,
finishing meals or snacks at least 30 min prior to the saliva collection; avoiding eating
bananas and chocolate on the collection day; drinking water up to 10 min before each
sample collection; no tooth brushing with toothpaste during the sampling period;
avoiding drinking coffee, cola and alcohol at least 4 hours prior to the collection; and
avoiding taking aspirin or ibutrofen during the collection day (Pandi-Perumal et al.,
2007).
Actigraphy was applied to assess the sleep-wake pattern using the Actiwatch 2
(Philips Respironics, Andover, MA, USA). This device was placed on participants’ nondominant wrist. The actimeter was employed over 7 days; and analysis used records from
6 completes days. Activity counts were recorded every minute and actigraphy recordings
were accompanied by self-reporting sleep log. The device contained a button to mark
events, and participants were instructed to push this button when going to sleep and
waking up in the morning. They were also asked not to remove the device during this
collection period. Parameters of the sleep-wake cycle were classified in variables of the
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wake and sleep phases. Variables of the wake phase were: sum of all valid physical
activity counts in average, average activity counts (the average of all valid physical
activity counts during wake time), and immobile time. Variables of the sleep phase were
the following: sleep duration (amount of time between sleep onset and waking); sleep
latency (time elapsed between going to bed and sleep onset), wake after sleep onsetWOSA (amount of time classified as awake during the sleep time) and average activity
counts (the average of all valid physical activity counts during sleep time).

Statistical Analysis
Data analysis was performed using SPSS 21.0 software (Armonk, NY, USA). The
Kolmogorov-Smirnov test was used to examine the distribution of the continuous
variables. The independent t-test was used to compare groups in regards to mean age,
BMI, ARES score and BDI, as well as, melatonin concentrations, the differences in the
wake and sleep variables, mean light exposition per minute and average of all light in
Lux. Analysis of covariance was conducted to control for risk of OSA. The Spearman’s
and Pearson’s correlation tests were used to examine the intra-group correlation among
wake and sleep variables, melatonin concentration, and HbA1c. The chi-square Fisher’s
exact test was used to compare proportions of males and females and the presence of
hypertension by group. Comparisons between good control and poor control were
assessed using Mann-Whitney U test. The level of significance was set at p<.05.
Actimetry variables were analyzed by Respironics Actiware 5.70.1 software (Philips
Respironics, Andover, MA, USA).
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Results
There were no significant differences in gender, weight, height and BMI between
the diabetic and the control group (Table 1). Also, there was no significant difference in
the depression scale measured by BDI (Diabetics 5.7 ± 5.8 vs. Controls 3.5 ± 3.4; p=.13).
In regards to the risk for obstructive sleep apnea, the groups were significantly different
(p=.009). The diabetic group had higher scores indicating an increased risk for OSA (5.8
± 2.7 vs. 3.4 ± 2.7; p=.009).

Table 1 - Mean±SD of subjects’characteristics according to group.
Diabetic
Group
21

Control
Group
21

38.1
61.9

42.9
57.1

.50

59.0 ± 8.6

59.5 ± 8.5

.68

79.0± 15.3

.33

1.7 ± .1

.91

27.6 ± 7.2

28.8± 4.3

.21

High blood pressure (%)

85.7

14.3

<.01*

Duration of disease (years)

11.7 ± 9.6

Variables
n
Gender a (%) Male
Female
Ageb (years)
b

Weight (Kg)

77.0 ±
15.0
1.7 ± .1

Heightb (m)
b

2

BMI (kg/m )
a

b

HbA1c (%)

7.7 ± 1.4

Diabetes treatment (%)
Oral drug
Insulin
n, number of subjects per group
a
Fisher’s test comparisons
b
Independent test comparisons
*significant difference (p<.05)

61.9
38.1
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p
value

Salivary melatonin concentrations were measured 2 hours before bed time, at bed
time and at wake time in the following morning. There was a significant difference in
mean melatonin concentrations at bed time between diabetic subjects and healthy
controls (11.7 ± 7.2pg/ml vs. 24.1 ± 10.8pg/ml; p<.01). Additionally, when normalized
for baseline and then analyzed for percent change in melatonin level, there was a
significant difference between groups between the sample collected two hours before bed
time and the sample collected at bed time (31.9 ± 62.7 vs. 174.3 ± 193.3; p=.048) (Fig.
1).
A

B
*

*

Figure1: A, mean±SD melatonin concentrations in diabetic and control groups; B,
mean±SD melatonin percent change in melatonin level in diabetic and control groups.
*p<.05

Analysis on actigraphic variables showed that, compared to controls, the diabetic
group presented a significant lower level of activity during the wake phase. The sum of
all valid physical activity counts (average total activity count) and the average of the
activity counts were significantly lower in the diabetic group than in the control group
(p=.02 and p=.02 respectively) (Table 2). Moreover, diabetics tended to spend more time
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immobile while awake, although there was no significant difference between groups
(p=.09) (Table 2).
Results on the sleep phase showed that the diabetics slept significantly less hours
per night (p=.03), and more inefficiently than the healthy controls (p=.02) (Table 2). On
regards to latency, there was no significant difference between groups (p=.60); however,
the diabetic group showed higher latency in minutes than controls. There was also a
borderline significant difference in wake after sleep onset (WASO) in minutes between
groups; the diabetic group spent more time awake after the sleep onset compared to
controls (p=.07). In average, the activity counts during sleep was significantly higher in
diabetics than in the control group (p=.02). Figure 2 demonstrates the activity pattern
during the six days of analysis of a diabetic and a healthy control. It indicates a
significant difference between the two groups in relation to total activity (p= .02), with
smaller values for diabetics.
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Table 2 – Comparison of actigraphic variables in diabetic and control group.
Variables

Diabetic Group

Control Group

Mean

SD

Mean

SD

219927.3

56702.7

275444.0

91789.6

.02*

Average activity countsa

261.8

62.0

325.6

97.4

.02*

Immobile timea (min)

132.9

81.7

99.4

34.1

.09

424654.1

263551.6

478923.9

414253.4

.61

477.5

297.2

531.7

431.1

.64

Sleep durationa (min)

320.9

66.0

363.7

56.2

.03*

Efficiencya (%)

68.7

12.4

77.1

9.3

.02*

Latencya (min)

16.9

16.2

14.6

11.7

.60

WASOa,b (min)

122.9

60.5

89.0

55.9

.07

Average activity countsa

19.8

13.8

9.6

5.3

.02*

p

Wake phase
Average total activitya

Total Exposurea (Lux by
minute)
Average lighta (Lux)
Sleep phase

a

Independent t test comparisons
WASO = wake after sleep onset
*significant difference (p<.05)
b
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A

B

Figure 2 – Activity count per epoch in the six days of analysis. A, activity level of a
diabetic subject; and B, activity level of a healthy control.

There were no significant differences between groups in the sum of all light
exposition (Lux multiplied by minute) (424654.1 ± 263551.6 vs. 478923.9 ± 414253.4;
p=.61) and average of all valid light (Lux) (477.5 ± 297.2 vs. 531.7 ± 431.1; p=.64)
during the wake interval (Table 2). Based on the diabetic subjects classified as good (<
7.5%) and fair-poor controls (≥7.5%), the poor controls were significantly less exposed to
light per minute than good controls (548322.3 ± 257660.0 vs. 288619.2 ± 203310.3;
p=.02); and there was a significantly less amount of all valid light in Lux for the poor
controls, when compared to good controls (617.8 ± 298.0 vs. 323.2 ± 217.2; p=.02).
Actigraphic variables comparisons between good and fair-poor controls revealed
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that there were no significant differences in these variables (p>.05; data not shown), with
the exception to latency, in which the poor controls demonstrated longer latency time in
minutes compared to good controls (Min:Max; Median) (0.6: 24.0; 4.6 vs. 3:5, 7.0; 28.4;
p=.005).
The corresponding parameters of the sleep-wake cycle of the day of melatonin
collection was individually analyzed and correlated with melatonin concentrations. In the
diabetic group, there were no significant correlations between melatonin concentrations
and variables of the wake phase (p>.05; data not shown). When analyzing correlations
with variables of the sleep phase, sleep efficiency was significantly correlated with
melatonin collected two hours before bed time (ρ=.61; p=.047). Additionally, there were
significant inverse associations between melatonin collected at two hours before bed time
and latency (ρ=-.87; p=.001), WASO (ρ=-.69; p=.02) and nocturnal activity (ρ =-.67;
p=.03). Also, there was a significant inverse relationship between latency and melatonin
collected at bed time (ρ =-.69; p=.02) (Table 3).

Table 3: Correlation coefficients and p values recorded when analyzing the correlation
between melatonin concentrations and variables of the sleep phase.
Sleep phase variables
M1
M2
M3
ρ

p

ρ

p

ρ

p

Efficiency (%)a

.61

.047*

.35

.30

.57

.06

Latency (min)b

-.87

.001*

-.69

.02*

-.54

.09

WASOa

-.69

.02*

-.52

.10

-.60

.05

Average activity countsa

-.67

.03*

-.56

.07

-.55

.08

M1, melatonin collected two hours before bed time
M2, melatonin collected at bed time
M3, melatonin collected at wake up in the morning
a
Pearson’s Correlation
b
Spearman’s Correlation
*significant difference (p<.05)
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Discussion
This study found alterations in the homeostatic and circadian controls of the
sleep-wake cycle on T2DM that were significantly related to melatonin concentrations.
Actigraphic analysis during the wake phase demonstrated that diabetic subjects showed
lower daily activity. Additionally, there was a significant decrease in sleep duration and
efficiency; and higher activity counts during the sleep phase in the diabetic group when
compared to controls. These findings suggest that T2DM presents disturbances in the
homeostatic drive to sleep; moreover, in addition to the lower melatonin amplitude
observed in these subjects, the decrease in the amplitude of the activity rhythm may also
be involved in circadian alterations of the sleep-wake cycle.
Melatonin concentrations were significantly lower at bed time in the diabetic
group when compared to controls. Although we did not detect significant differences in
melatonin levels between groups when analyzing concentrations at 2 hours before bed
time and at wake up in the morning, the diabetic subjects had lower melatonin levels in
all three measurements. These findings reveal a possible alteration in the amplitude of the
melatonin rhythm; which was previously reported by other studies (Arendt et al., 1982;
Tutuncu et al., 2005; Mantele et al., 2012). Tutuncu et al., 2005, observed significant
lower values of melatonin and disturbances in melatonin rhythm in T2DM (Tutuncu et
al., 2005). These authors suggested that autonomic neuropathy found in diabetic patients
is the most important complication with concerning the decreased in melatonin secretion
(Tutuncu et al., 2005). A recent study by McMullan et al., 2013, reported that the
decrease in melatonin secretion is associated with an increased chance in developing
T2DM (McMullan et al., 2013). Some studies have suggested the relationship between
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impaired melatonin levels and signaling being involved in the disturbance of insulin
sensitivity, and as a consequence, leading to T2DM (Peschke et al., 2006; Mantele et al.,
2012).
Melatonin appears to influence the sleep-wake cycle by interaction with the
circadian and homeostatic processes. Exogenous melatonin is able to shift the circadian
rhythm to earlier or later based on the time of the day that it is provided (process C)
(Lewy et al., 1998). On the other hand, melatonin may also influence the homeostatic
drive to sleep due to its “hypnotic” property (process S) (Mendelson, 1997). Furthermore,
the rapid increase in melatonin in blood is responsible for the abrupt increase in sleep
propensity and inhibition of neural activities in the SCN, which suppresses the circadian
drive (Lavie, 1997). Similarly to T2DM, studies on Alzheimer disease also observed
decrease in melatonin amplitude and irregularities on melatonin patterns (Cardinali et al.,
2002). It has been implied that the signal strength to clock resetting by the melatonin
rhythm has been disrupted, as well as the internal synchronizing time cue (Cardinali,
2010). Changes in melatonin secretion observed in Alzheimer patients might be
responsible for sleep disruption, nightly restlessness and sundowing (Cardinali et al.,
2002). In our study, it was not possible to assess the entire melatonin rhythm to better
analyze endogenous circadian signaling; however, the decrease in melatonin amplitude
may be affecting the circadian and homeostatic processes, influencing the suppression of
the circadian drive, and at the same time decreasing the homeostatic drive to sleep.
Moreover, these dysfunctions may be related to the sleep disturbances found in our study.
Analysis during the wake phase demonstrated that the level of physical activity in
T2DM was significantly lower when compared to the control group. These results
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suggest a decrease in the amplitude of the activity rhythm in the diabetic group, most
likely due to the increased sedentary behavior. It has been previously reported that lower
amplitude might decrease the stimuli sent to structures that regulate the circadian rhythm
(Winget et al., 1972), and possibly affecting the circadian drive. Immobilized healthy
subjects that were induced to forced hypokinesis by resting in bed resulted in disrupted
sleep and reduced amplitude of the circadian body temperature rhythm; and as a
consequence, it leaded to dessynchonization with the environment (Winget et al., 1972).
The decrease in the amplitude of the rest-activity rhythm was previously identified in
Parkinson’s disease (Whitehead et al., 2008), Alzheimer (Van Someren et al., 1996) and
stroke (Cavalcanti, 2012; Cavalcanti, 2013), but to our knowledge, it has not been
reported in T2DM. Physical activity has a dual function that should be further considered
for diabetes. It is a synchronizer for the sleep-wake cycle; and it is also important for
prevention and treatment of diabetes, mainly due to its potential to reduce insulin
resistance (Gill & Malkova, 2006; Ross & Despres, 2009; Zuo et al., 2012). Perhaps the
decrease in the activity rhythm observed in T2DM may be one of the factors influencing
the disturbances in the circadian function, and in addition, together with the decrease in
melatonin concentrations, may further disrupt the glucose and insulin metabolism. In line
with this explanation, studies have shown a relationship between the combination of low
physical activity and insufficient amount of sleep and insulin resistance and reduced
glucose tolerance (Nedeltcheva et al., 2009a; Zuo et al., 2012). Zuo et al., 2012 observed
that adequate sleep duration together with different types of physical activity may assist
the decrease of insulin resistance (Zuo et al., 2012). Moreover, Bromley et al., 2012
suggested that one of the factors mediating chronic inadequate sleep and metabolic
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morbidity is related to physical activity decrease (Bromley et al., 2012). Furthermore,
studies have shown associations between exercise and quality of sleep (Paparrigopoulos
et al., 2010), sleep restriction and decreased physical activity (Nedeltcheva et al., 2009a;
Bromley et al., 2012), insomnia, and decreased physical activity in prediabetic subjects
(Chasens & Yang, 2012). Finally, sleep disturbances are considered risk factor for
developing T2DM (McMullan et al., 2013). Further analysis should be considered to
further assess the influence of physical activity on sleep-wake cycle synchronization as
well as on melatonin amplitude, and glucose and insulin metabolism in T2DM.
In regards to the relationship between physical activity and melatonin
concentrations, we did not find a significant association. Few studies have assessed the
role of physical activity on melatonin levels, but we found no studies analyzing this
relationship in T2DM. A study on shift worker nurses reported similar results (Grundy et
al., 2009); however, another study found an inverse association between sedentary
behavior and physical activity during the biological relevant timeframe (3PM to 7AM)
and melatonin levels on urinary samples (McPherson et al., 2011). Although, results on
the relationship between melatonin concentrations and physical exercise have been
conflicting, growing sources of evidences have demonstrated direct and indirect benefits
from melatonin on physical activity and on diabetes. Previous studies indicated that
melatonin influences physical performance (Escames et al., 2012), preserves glycogen
stores (Kaya et al., 2006), reduces oxidative stress and inflammation in cardiac and
skeletal muscle (Escames et al., 2006; Mukherjee et al., 2010), protects against heart
damage by acute exercise (Veneroso et al., 2009), has protective effects toward obesityrelated metabolic complications (Cardinali et al., 2011), improves glycemic control (Agil
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et al., 2012), protects pancreatic b-cells against functional overcharge and, as a
consequence, against the development of T2DM (Peschke et al., 2012). Furthermore, a
study on T2DM suggested that alteration on melatonin rhythm amplitude may be
functionally related to changes in insulin secretion (Mantele et al., 2012). Associations
between physical activity and melatonin concentrations on T2DM, as well as the
influence of these variables on the circadian and homeostatic drive should be further
explored. Futures studies should examine the responses of different levels of physical
activity at different times of the day on the circadian rhythm synchronization, while
analyzing changes in melatonin concentrations on T2DM.
The sleep phase assessment of diabetic subjects showed that they slept
significantly less, with less efficiency and had higher scores of activity counts than
healthy controls. These findings suggest they may have a disturbance in the homeostatic
drive to sleep. Similar results on these variables were previously reported by Trento et al.,
2008 who reported lower sleep maintenance, lower efficiency, and more movement while
in bed in the T2DM group (Trento et al., 2008). The authors argued that sleep
disturbances found in this population could be related to impaired glucose tolerance and
consequences of the disease itself (Trento et al., 2008). Tsujimura et al., 2009 also
reported increased activity when subjects were in bed and long wake episodes during
sleep time. They found an inverse relationship between activity counts while in bed and
wake episodes with HbA1c level (Tsujimura et al., 2009). Our study did not find a
significant difference between diabetic and controls regarding WOSA. In regards to the
relationship between HbA1c and actigraphs parameters, we only found a positive
correlation between HbA1c and onset latency. These findings are similar to those
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reported by Rajendran et al. who did not find relationships between HbA1c and sleep
dysfunction (Rajendran et al., 2012). More studies need to be conducted to assess the
correlations between glucose tolerance and sleep-wake cycle in order to better direct
therapeutic procedures that might help to achieve a better glycemic control.
The analysis of correlation between melatonin concentration and sleep parameters
demonstrated that melatonin collected two hours before bed time was positively
correlated with sleep efficiency. Additionally, inverse associations were found between
melatonin collected two hours before bed time and WASO and nocturnal activity. Onset
latency was found to be inversely correlated with melatonin collected two hours before
bed time and at bed time. Similar results on the analysis of correlation between melatonin
and sleep parameters have been previously reported. Increased melatonin concentration
correlated with decrease onset latency, increase sleep efficiency and decrease nocturnal
activity during sleep (Waldhauser et al., 1990; Nunes et al., 2008). A study by
Waldhauser et al., 1990 indicated that the administration of exogenous melatonin in
young healthy volunteers improves sleep latency, number of awakenings, and sleep
efficiency (Waldhauser et al., 1990). Similarly to our findings, this study found no
association between melatonin and with total sleep time. Garfinkel et al., 2011 assessing
the effect of exogenous administration of melatonin in T2DM with insomnia found
improvement on sleep maintenance and glycemic control (Garfinkel et al., 2011). They
found improvements in sleep efficiency, WASO, and number of awakenings with
prolonged-release melatonin when compared to placebo (Garfinkel et al., 2011). This
study supports the use of melatonin to improve sleep maintenance in T2DM with
insomnia, also suggesting that exogenous melatonin may also be beneficial to increase
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glycemic control (Garfinkel et al., 2011). Based on these findings and on the hypothesis
that endogenous melatonin have a direct effect on sleep regulation (Tzischinsky et al.,
1993), the decrease in melatonin amplitude observed in T2DM, might be one of the
factors influencing the homeostatic control that lead to impairment on sleep
maintenance.
Light is the most important synchronizer for the circadian system and directly
influences melatonin amplitude (Lewy et al., 1980; Nagtegaal, 2002). High Light
intensities (2500 Lux) produce suppression of melatonin in short period of time (Lewy et
al., 1980; Pandi-Perumal et al., 2007); bright light exposition during the day may increase
melatonin amplitude at night; while light exposure during night time decrease
endogenous melatonin and may contribute to the incidence of diabetes (Hikichi et al.,
2011). Results of our study indicated no significant differences between groups in mean
light exposure and average of total amount of light in Lux recorded during the wake
phase. Also, there were no significant correlations between these variables and melatonin
concentration in the diabetic group. One of the possible reasons for the lack of
correlations might be related to disturbances in the strength of the light signal to reset the
clock. Ophthalmic disturbances can impair the synchronization by light and have been
previously reported in diabetic subjects as possibly disturbing photic input to the
circadian system (Brainard et al., 2001). Hikichi et al., 2011 reported that diabetic
patients with retinopathy presented more apparent alteration of melatonin when compared
to diabetic subjects without retinopathy (Hikichi et al., 2011). These authors suggested
that dysfunctional retinal light perception may be associated with the decrease melatonin
levels found in diabetic subjects (Hikichi et al., 2011). Although we have not clinically
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assessed presence of retinopathy in our sample, around 76% of our subjects reported
having some source of ophthalmic complaint. Possibly, the visual disturbances reported
in our sample may also be related to the alteration in melatonin amplitude. In aging
process, the decrease in the photic stimuli is related to aging changes in retinal function
that can lead to less short-wavelength light stimuli, what is indicated to be imperative for
circadian light input (Herljevic et al., 2005). This reduction in the circadian response to
light may result in a weaker circadian drive (Cajochen et al., 2006). Perhaps, diabetic
subjects with increased photic resistance can benefit from stimuli from other zeitgebers,
such as meal time and physical activity to assist the entrainment to changes in the lightdark cycle and compensate the possible decrease in the circadian drive due to ophthalmic
dysfunction.
This study has several limitations. First, it is an observational study and we can
not draw conclusions on causality. Second, only approximately half of our sample had
the melatonin concentrations analyzed, and the collection was done for only one night.
Third, it is possible that our subjects did not completely follow our instructions on
melatonin collections at home, and it might as well have influenced the results observed.
Fourth, because melatonin concentrations were measured only three times, it was not
possible to show the complete melatonin rhythm over 24 hours period.

Conclusions
In summary, in this study we found disturbances in the circadian and homeostatic
control of the sleep-wake cycle in T2DM. Additionally, we identified associations
between salivary melatonin concentration and sleep efficiency, onset latency, WASO and

60

night activity during sleep phase. Further studies should address whether stimulating
other zeitgebers, such as physical activity and meal time, as well as interventions using
sleep hygiene, in conjunction with or instead of exogenous melatonin, would alter any of
these sleep-wake parameters and therefore compensate the impaired sleep-wake cycle
due to altered circadian and homeostatic drives.

Acknowledgments: We acknowledge the financial support for this research from the
Clinical Research Molecular Laboratory and the Physical Therapy department, School of
Allied Health Professions, Loma Linda University.

61

References
Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G. (2012). Melatonin
improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res.
52: 203-210.
Arendt J, Hampton S, English J, Kwasowski P, Marks V. (1982). 24-hour profiles of
melatonin, cortisol, insulin, C-peptide and GIP following a meal and subsequent
fasting. Clin Endocrinol (Oxf). 16: 89-95.
Borbely A A. (1982). A two process model of sleep regulation. Hum Neurobiol. 1: 195204.
Brainard G C, Hanifin J P, Greeson J M, Byrne B, Glickman G, Gerner E, Rollag M D.
(2001). Action spectrum for melatonin regulation in humans: evidence for a novel
circadian photoreceptor. J Neurosci. 21: 6405-6412.
Bromley L E, Booth J N, 3rd, Kilkus J M, Imperial J G, Penev P D. (2012). Sleep
restriction decreases the physical activity of adults at risk for type 2 diabetes.
Sleep. 35: 977-984.
Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. (2006). Age-related
changes in the circadian and homeostatic regulation of human sleep. Chronobiol
Int. 23: 461-474.
Cardinali D P, Brusco L I, Liberczuk C, Furio A M. (2002). The use of melatonin in
Alzheimer's disease. Neuro Endocrinol Lett. 23 Suppl 1: 20-23.
Cardinali D P, Cano P, Jimenez-Ortega V, Esquifino A I. (2011). Melatonin and the
metabolic syndrome: physiopathologic and therapeutical implications.
Neuroendocrinology. 93: 133-142.
Cardinali D P S, P. A. . (2010). Chronophysiology of Melatonin: Therapeutical
Implications. The Open Neuroendocrinology Journal. 3: 72-84.
Cavalcanti P, Campos, T, Araujo, J. (2012). Actigraphic analysis of the sleep-wake cycle
and physical activity level in patients with stroke: implications for clinical
practice. Chronobiol Int. 29: 1267-1272.
Cavalcanti P, Campos, T, Araujo, J. (2013). Circadian and homeostatic changes of sleepwake and quality of life in stroke: Implications for neurorehabilitation.
NeuroRehabilitation. 32: 337-343.
Chasens E R, Yang K. (2012). Insomnia and physical activity in adults with prediabetes.
Clin Nurs Res. 21: 294-308.

62

Dijk D J, von Schantz M. (2005). Timing and consolidation of human sleep, wakefulness,
and performance by a symphony of oscillators. J Biol Rhythms. 20: 279-290.
Escames G, Lopez L C, Tapias V, Utrilla P, Reiter R J, Hitos A B, Leon J, Rodriguez M
I, Acuna-Castroviejo D. (2006). Melatonin counteracts inducible mitochondrial
nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of
septic mice. J Pineal Res. 40: 71-78.
Escames G, Ozturk G, Bano-Otalora B, Pozo M J, Madrid J A, Reiter R J, Serrano E,
Concepcion M, Acuna-Castroviejo D. (2012). Exercise and melatonin in humans:
reciprocal benefits. J Pineal Res. 52: 1-11.
Gangwisch J E, Heymsfield S B, Boden-Albala B, Buijs R M, Kreier F, Pickering T G,
Rundle A G, Zammit G K, Malaspina D. (2006). Short sleep duration as a risk
factor for hypertension: analyses of the first National Health and Nutrition
Examination Survey. Hypertension. 47: 833-839.
Gangwisch J E, Malaspina D, Boden-Albala B, Heymsfield S B. (2005). Inadequate sleep
as a risk factor for obesity: analyses of the NHANES I. Sleep. 28: 1289-1296.
Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. (2011). Efficacy and
safety of prolonged-release melatonin in insomnia patients with diabetes: a
randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 4: 307313.
Gill J M, Malkova D. (2006). Physical activity, fitness and cardiovascular disease risk in
adults: interactions with insulin resistance and obesity. Clin Sci (Lond). 110: 409425.
Grundy A, Sanchez M, Richardson H, Tranmer J, Borugian M, Graham C H, Aronson K
J. (2009). Light intensity exposure, sleep duration, physical activity, and
biomarkers of melatonin among rotating shift nurses. Chronobiol Int. 26: 14431461.
Hartemann-Heurtier A, Sultan S, Sachon C, Bosquet F, Grimaldi A. (2001). How type 1
diabetic patients with good or poor glycemic control cope with diabetes-related
stress. Diabetes Metab. 27: 553-559.
Herljevic M, Middleton B, Thapan K, Skene D J. (2005). Light-induced melatonin
suppression: age-related reduction in response to short wavelength light. Exp
Gerontol. 40: 237-242.
Hikichi T, Tateda N, Miura T. (2011). Alteration of melatonin secretion in patients with
type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 5: 655660.

63

Kaya O, Gokdemir K, Kilic M, Baltaci A K. (2006). Melatonin supplementation to rats
subjected to acute swimming exercise: Its effect on plasma lactate levels and
relation with zinc. Neuro Endocrinol Lett. 27: 263-266.
Khullar A. (2012). The Role of Melatonin in the Circadian Rhythm Sleep-Wake Cycle.
Psychiatric Times. 29.
Knutson K L, Ryden A M, Mander B A, Van Cauter E. (2006). Role of sleep duration
and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med.
166: 1768-1774.
Lavie P. (1997). Melatonin: role in gating nocturnal rise in sleep propensity. J Biol
Rhythms. 12: 657-665.
Levendowski D. J OR P D, Carper D. L, Berka C, Westbrook P. R. (2007). Assessment
of Obstructive Sleep Apnea Risk and Severity in Truck Drivers: Validation of a
Screening Questionnaire. Sleep Diagnosis and Therapy. 2: 20-26.
Lewy A J, Bauer V K, Ahmed S, Thomas K H, Cutler N L, Singer C M, Moffit M T,
Sack R L. (1998). The human phase response curve (PRC) to melatonin is about
12 hours out of phase with the PRC to light. Chronobiol Int. 15: 71-83.
Lewy A J, Wehr T A, Goodwin F K, Newsome D A, Markey S P. (1980). Light
suppresses melatonin secretion in humans. Science. 210: 1267-1269.
Mantele S, Otway D T, Middleton B, Bretschneider S, Wright J, Robertson M D, Skene
D J, Johnston J D. (2012). Daily rhythms of plasma melatonin, but not plasma
leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. PLoS
One. 7: e37123.
McMullan C J, Schernhammer E S, Rimm E B, Hu F B, Forman J P. (2013). Melatonin
secretion and the incidence of type 2 diabetes. JAMA. 309: 1388-1396.
McPherson M, Janssen I, Grundy A, Tranmer J, Richardson H, Aronson K J. (2011).
Physical activity, sedentary behavior, and melatonin among rotating shift nurses.
J Occup Environ Med. 53: 716-721.
Mendelson W B. (1997). Efficacy of melatonin as a hypnotic agent. J Biol Rhythms. 12:
651-656.
Mukherjee D, Roy S G, Bandyopadhyay A, Chattopadhyay A, Basu A, Mitra E, Ghosh A
K, Reiter R J, Bandyopadhyay D. (2010). Melatonin protects against
isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J
Pineal Res. 48: 251-262.
Nagtegaal J E (2002). Chronobiological, clinical and pharmacological aspects of
melatonin in human circadian rhythm dysfunction. Treatise on pineal gland and

64

melatonin. C Haldar, M Singaravel and S K Maitra. Enfield, NH, Science
Publishers, Inc.: 461–489.
Nakanishi-Minami T, Kishida K, Funahashi T, Shimomura I. (2012). Sleep-wake cycle
irregularities in type 2 diabetics. Diabetol Metab Syndr. 4: 18.
Nedeltcheva A V, Kessler L, Imperial J, Penev P D. (2009). Exposure to recurrent sleep
restriction in the setting of high caloric intake and physical inactivity results in
increased insulin resistance and reduced glucose tolerance. J Clin Endocrinol
Metab. 94: 3242-3250.
Nishida S. (2005). Metabolic effects of melatonin on oxidative stress and diabetes
mellitus. Endocrine. 27: 131-136.
Nunes D M, Mota R M, Machado M O, Pereira E D, Bruin V M, Bruin P F. (2008).
Effect of melatonin administration on subjective sleep quality in chronic
obstructive pulmonary disease. Braz J Med Biol Res. 41: 926-931.
Pandi-Perumal S R, Smits M, Spence W, Srinivasan V, Cardinali D P, Lowe A D,
Kayumov L. (2007). Dim light melatonin onset (DLMO): a tool for the analysis
of circadian phase in human sleep and chronobiological disorders. Prog
Neuropsychopharmacol Biol Psychiatry. 31: 1-11.
Paparrigopoulos T, Tzavara C, Theleritis C, Soldatos C, Tountas Y. (2010). Physical
activity may promote sleep in cardiac patients suffering from insomnia. Int J
Cardiol. 143: 209-211.
Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, Spessert R,
Muhlbauer E. (2006). Diabetic Goto Kakizaki rats as well as type 2 diabetic
patients show a decreased diurnal serum melatonin level and an increased
pancreatic melatonin-receptor status. J Pineal Res. 40: 135-143.
Peschke E, Hofmann K, Ponicke K, Wedekind D, Muhlbauer E. (2012). Catecholamines
are the key for explaining the biological relevance of insulin-melatonin
antagonisms in type 1 and type 2 diabetes. J Pineal Res. 52: 389-396.
Plantinga L, Rao M N, Schillinger D. (2012). Prevalence of self-reported sleep problems
among people with diabetes in the United States, 2005-2008. Prev Chronic Dis. 9:
E76.
Rajendran A, Parthsarathy S, Tamilselvan B, Seshadri K G, Shuaib M. (2012).
Prevalence and correlates of disordered sleep in southeast asian indians with type
2 diabetes. Diabetes Metab J. 36: 70-76.
Robeva R, Kirilov G, Tomova A, Kumanov P. (2008). Melatonin-insulin interactions in
patients with metabolic syndrome. J Pineal Res. 44: 52-56.

65

Ross R, Despres J P. (2009). Abdominal obesity, insulin resistance, and the metabolic
syndrome: contribution of physical activity/exercise. Obesity (Silver Spring). 17
Suppl 3: S1-2.
Scheer F A, Czeisler C A. (2005). Melatonin, sleep, and circadian rhythms. Sleep Med
Rev. 9: 5-9.
Tasali E, Leproult R, Spiegel K. (2009). Reduced sleep duration or quality: relationships
with insulin resistance and type 2 diabetes. Prog Cardiovasc Dis. 51: 381-391.
Trento M, Broglio F, Riganti F, Basile M, Borgo E, Kucich C, Passera P, Tibaldi P,
Tomelini M, Cavallo F, Ghigo E, Porta M. (2008). Sleep abnormalities in type 2
diabetes may be associated with glycemic control. Acta Diabetol. 45: 225-229.
Tsujimura T, Matsuo Y, Keyaki T, Sakurada K, Imanishi J. (2009). Correlations of sleep
disturbance with the immune system in type 2 diabetes mellitus. Diabetes Res
Clin Pract. 85: 286-292.
Tutuncu N B, Batur M K, Yildirir A, Tutuncu T, Deger A, Koray Z, Erbas B, Kabakci G,
Aksoyek S, Erbas T. (2005). Melatonin levels decrease in type 2 diabetic patients
with cardiac autonomic neuropathy. J Pineal Res. 39: 43-49.
Tzischinsky O, Shlitner A, Lavie P. (1993). The association between the nocturnal sleep
gate and nocturnal onset of urinary 6-sulfatoxymelatonin. J Biol Rhythms. 8: 199209.
van Someren E J, Hagebeuk E E, Lijzenga C, Scheltens P, de Rooij S E, Jonker C, Pot A
M, Mirmiran M, Swaab D F. (1996). Circadian rest-activity rhythm disturbances
in Alzheimer's disease. Biol Psychiatry. 40: 259-270.
Veneroso C, Tunon M J, Gonzalez-Gallego J, Collado P S. (2009). Melatonin reduces
cardiac inflammatory injury induced by acute exercise. J Pineal Res. 47: 184-191.
Waldhauser F, Saletu B, Trinchard-Lugan I. (1990). Sleep laboratory investigations on
hypnotic properties of melatonin. Psychopharmacology (Berl). 100: 222-226.
Whitehead D L, Davies A D, Playfer J R, Turnbull C J. (2008). Circadian rest-activity
rhythm is altered in Parkinson's disease patients with hallucinations. Mov Disord.
23: 1137-1145.
Winget C M, Vernikos-Danellis J, Cronin S E, Leach C S, Rambaut P C, Mack P B.
(1972). Circadian rhythm asynchrony in man during hypokinesis. J Appl Physiol.
33: 640-643.
Zuo H, Shi Z, Yuan B, Dai Y, Hu G, Wu G, Hussain A. (2012). Interaction between
physical activity and sleep duration in relation to insulin resistance among nondiabetic Chinese adults. BMC Public Health. 12: 247.

66

CHAPTER FOUR
DISCUSSION

According to the nonparametric methodology approach, it was found that
diabetics presented lower IS (p=.03), higher IV (p=.046) and lower rhythm amplitude
(p=.02) when compared to healthy controls. Similar results were observed by Van
Someren et al. (1996) in Alzheimer patients. Based in this study, lower values of IS
represents less consistency across days of the daily circadian signal; also, revealing a
potential disturbance in the strength of its coupling to stable zeitgebers. In regards to IV,
the diabetic group showed significantly higher values when compared to controls and
higher values of IV are indicative of more fragmented rhythm. Similar results were
observed in Parkinson’s disease by Whitehead et al. (2008). This study reported that on
the Parkinson’s group, it was found a more fragmented rest-activity rhythm with
constants transitions from high to low periods of activity. In T2DM, studies have shown
that nocturia is a significant variable that is positively correlated with difficulty to
maintain sleep (Lamond et al., 2000) and it might as well contribute to increase IV in the
diabetic population. Lower peak of physical activity and lower rhythm amplitude were
also observed in Parkinson’s disease and stroke. Motor alterations on stroke patients
could be influencing the expression of this variable (Cavalcanti, 2012). Similarly, we
observed lower levels of physical activity and low rhythm amplitude in the diabetic
group. This finding could be related to the increased sedentary activity commonly found
in these individuals.
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Actigraph studies on T2DM subjects revealed that sleep-wake cycle irregularities
are more frequent in diabetic individuals than in the healthy controls. Tsujimura et al.
(2009) reported higher scores of night activity in the diabetic group when compared to
controls (Tsujimura et al., 2009). Additionally, they reported that higher fasting plasma
glucose and HbA1c values were positively correlated with pronounced sleep and
circadian rhythm disturbances. Our study also found higher activity level in the diabetic
group during night time (measured by L5, related to the least 5 hours of activity, night
activity); however, we did not find significant relationships between HbA1c and the
circadian variables. Nakanishi-Minami et al., 2012 reported that T2DM subjects tended to
go to bed later and wake up later; and had higher daytime sleepiness compared to
controls (Nakanishi-Minami et al., 2012). These authors suggested that irregular sleepwake cycle patters and short and long sleep may enhance dysfunction in the glucose
metabolism.
The sleep phase assessment of diabetic subjects showed that they slept
significantly less, with less efficiency and had higher scores of activity counts than
healthy controls. These findings suggest they may have a disturbance in the homeostatic
drive to sleep. Similar results on these variables were previously reported by Trento et al.
(Trento et al., 2008). They reported lower sleep maintenance, lower efficiency, and more
movement while in bed in the T2DM group (Trento et al., 2008). The authors argued that
sleep disturbances found in this population could be related to impaired glucose tolerance
and consequences of the disease itself (Trento et al., 2008). Tsujimura et al. (Tsujimura et
al., 2009) also reported increased activity when subjects were in bed and long wake
episodes during sleep time. They found an inverse relationship between activity counts
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while in bed and wake episodes with HbA1c level (Tsujimura et al., 2009). Our study did
not find a significant difference between diabetic and controls regarding WOSA. In
regards to the relationship between HbA1c and actigraphs parameters, we only found a
positive correlation between HbA1c and onset latency. These findings are similar to those
reported by Rajendran et al. who did not find relationships between HbA1c and sleep
dysfunction (Rajendran et al., 2012). More studies need to be conducted to assess the
correlations between glucose tolerance and sleep-wake cycle in order to better direct
therapeutic procedures that might help to achieve a better glycemic control.
Sleep duration has been the focus of many studies on sleep disturbances in
T2DM. Moreover, it has been suggested that patients with T2DM sleep less than the
general population (Buxton et al., 2010). Sleep duration higher than 8 hours or less than 7
hours per night, have a moderate increased risk of all-cause mortality, as well as
cardiovascular disease, and developing symptomatic diabetes (Phillips et al., 2006).
Results from the Sleep Heart Health Study showed that sleeping 6 hours or less and
sleeping 9 hours or more per night have a greater prevalence of T2DM and impaired
glucose tolerance when compared to individuals sleeping 7–8 hours per night (Gottlieb et
al., 2005). A study by Chasens et al., 2009, reported that the mean sleep duration of the
diabetes group was 5.5 hours per night (Chasens et al., 2009). These authors described
this group as experiencing chronic sleep deprivation (Chasens et al., 2009). Our study
also observed similar results. It was found that the diabetic group slept on average 5.3
hours per night during the seven days of assessment; perhaps also experiencing chronic
sleep deprivation. Sleep deprivation has been described as linked with high glucose levels
due to reduced glucose metabolism, increased insulin resistance and high cortisol
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concentrations (Vgontzas et al., 1999; Gottlieb et al., 2005; Nedeltcheva et al., 2009a;
Spiegel et al., 2009; Buxton et al., 2010). Additionally, Sleep disruption may also be
associated with diabetes. A study reported that males who slept less than 5 hours per
night were twice as likely to develop diabetes than those who slept 7 hours per night
(Ayas et al., 2003; Yaggi et al., 2006). In a case-control study of T2DM, short sleep
duration and snoring frequency were associated with increased incident of T2DM
(McMullan et al., 2013). In our study, we have not found an association between sleep
duration and HbA1c; however, experimental analysis on healthy subjects found that
restricting sleep to 4h for a period of two or more nights was able to reduce glucose
tolerance by 40%, while also reducing acute insulin response to glucose by 30% (Spiegel
et al., 1999; Spiegel et al., 2005). Another study showed that even one night of sleep
restriction has negative effects on glucose metabolism in healthy individuals (Donga et
al., 2010).
In regards to sleep quality, Rajendranl et al., 2012 reported a high percentage of
T2DM with poor quality of sleep (PSQI score ≥5) (Rajendran et al., 2012). This finding
is in line with our results in which the diabetic group showed significantly poorer quality
of sleep compared to controls. Additionally, we found significant correlation between
glycemic control and quality of sleep. In a study conducted by Knutson et al., 2006,
involving 161 African Americans with T2DM, an association was observed between
lower sleep quality and poorer glucose control even after controlling for age, sex, BMI,
insulin use, and the presence of major complications of diabetes (Knutson et al., 2006).
Tsai et al., 2011, also demonstrated that poor sleep quality is significantly correlated with
worse glycemic control in patients with T2DM (Tsai et al., 2012). Similarly, Knutson et
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al., 2006 reported that sleep quality and duration were significant predictors of HbA1c.
These authors suggested the development of interventions that focus on optimizing sleep
duration and quality in order to improve glucose control in patients with T2DM (Knutson
et al., 2006).
Melatonin concentrations were significantly lower at bed time in the diabetic
group when compared to controls. Although we did not detect significant differences in
melatonin levels between groups when analyzing concentrations at 2 hours before bed
time and at wake up in the morning, the diabetic subjects had lower melatonin levels in
all three measurements. These findings reveal a possible alteration in the amplitude of the
melatonin rhythm; which was previously reported by other studies (Arendt et al., 1982;
Tutuncu et al., 2005; Mantele et al., 2012). Tutuncu et al. (Tutuncu et al., 2005) observed
significant lower values of melatonin and disturbances in melatonin rhythm in T2DM.
These authors suggested that autonomic neuropathy found in diabetic patients is the most
important complication with concerning the decreased in melatonin secretion (Tutuncu et
al., 2005). A recent study by McMullan et al. (McMullan et al., 2013) reported that the
decrease in melatonin secretion is associated with an increased chance in developing
T2DM. Some studies have suggested the relationship between impaired melatonin levels
and signaling being involved in the disturbance of insulin sensitivity, and as a
consequence, leading to T2DM (Peschke et al., 2006; Mantele et al., 2012).
Our study observed a strong significant inverse association between quality of
sleep and percent change between melatonin collected at bed time and at wake up in the
following morning; meaning that as lower the difference between the melatonin before
bed time and at awakening, the poorer the quality of sleep. Studies have previously
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reported administration of exogenous melatonin and improvement in quality of sleep
(Nunes et al., 2008; Luthringer et al., 2009). Garfinkel et al., 2011 using exogenous
melatonin found improvements in sleep maintenance assessed through actimetry in
diabetic subjects (Garfinkel et al., 2011).
In summary, we have shown that the sleep-wake cycle is disturbed in T2DM
when compared to healthy controls and it is mainly characterized by less consistency
across days of the daily circadian signal, higher rhythm fragmentation and lower rhythm
amplitude. Additionally, we found disturbances in the circadian and homeostatic control
of the sleep-wake cycle in T2DM and we identified associations between salivary
melatonin concentration and sleep efficiency, onset latency, WASO and night activity
during sleep phase.

Limitations and Suggestions for Futures Studies
Some limitations should be considered in this study. First, this is an observational
study and no causality can be assumed. Second, the lack of differences between good and
poor control and associations with HbA1c with the circadian variables may be a function
of the limited power of the diabetes sample because of the small sample size. Third, only
approximately half of our sample had the melatonin concentrations analyzed, and the
collection was done for only one night. Fourth, it is possible that our subjects did not
completely follow our instructions on melatonin collections at home, and it might as well
have influenced the results observed. Finally, because melatonin concentrations were
measured only three times, it was not possible to show the complete melatonin rhythm
over 24 hours period.
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Further studies should address whether stimulating other zeitgebers, such as
physical activity and meal time, as well as interventions using sleep hygiene, in
conjunction with or instead of exogenous melatonin, would alter any of the sleep-wake
parameters and therefore compensate the impaired sleep-wake cycle due to altered
circadian and homeostatic drives. Moreover, more studies are needed to test if increasing
the amplitude of the activity rhythm would result in more regulation of the sleep-wake
cycle, while analyzing melatonin amplitude, glucose and insulin metabolism in T2DM.
Futures approaches may also further examine associations between glycemic
control and the sleep-wake cycle with approaches that consider the influence of circadian
glucose variations throughout the day and meal times on the coupling of the rest-activity
rhythm to zeitgeber and rhythm fragmentation.
Perhaps, diabetic subjects with increased photic resistance can benefit from
stimuli from other zeitgebers, such as meal time and physical activity to assist the
entrainment to changes in the light-dark cycle and compensate the possible decrease in
the circadian drive due to ophthalmic dysfunction. Therefore, it is also recommend for
futures studies to perform a clinical assessment for ophthalmic disease on T2DM in order
to better assess the influence of light on these circadian variables.
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CHAPTER FIVE
CONCLUSIONS

The present study examined the sleep-wake cycle variations in T2DM using the
nonparametric methodological approach and the Two-process Model Theory to analyze
the circadian and homeostatic drives. This study found alterations in the homeostatic and
circadian controls of the sleep-wake cycle in T2DM that were significantly related to
melatonin concentrations. Actigraphic analysis during the wake phase demonstrated that
diabetic subjects showed lower daily activity. The findings revealed that T2DM
individuals demonstrate lower IS, indicating a lesser consistency across days of the daily
circadian signal; higher IV, showing greater variability within each 24-hour period; and
lower peak activity levels, indicated by lower activity rhythm amplitude compared to
healthy, age matched subjects. Additionally, there was a significant decrease in sleep
duration and efficiency; and higher activity counts during the sleep phase in the diabetic
group when compared to controls. These data together suggest that T2DM exhibit a
dysfunction in the sleep-wake cycle due to alterations in the circadian function as well as
in the homeostatic capacity to maintain sleep. Moreover, in addition to the lower
melatonin amplitude observed in these subjects, the decrease in the amplitude of the
activity rhythm may also be involved in the circadian alterations of the sleep-wake cycle.
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